MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors
Abstract
Authors
EL Atallah V Maheshwari MJ Mauro C Boquimpani D Réa A Hochhaus Y Minami L Saini R Corbin